CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

RATIONALE: Recent studies have demonstrated the feasibility of CD38-specific antibody constructs for in vivo imaging of multiple myeloma. However, detecting multiple myeloma in daratumumab-pretreated patients remains difficult due to overlapping binding epitopes of the CD38-specific imaging antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Pape, Luca Julius, Hambach, Julia, Gebhardt, Anna Josephine, Rissiek, Björn, Stähler, Tobias, Tode, Natalie, Khan, Cerusch, Weisel, Katja, Adam, Gerhard, Koch-Nolte, Friedrich, Bannas, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647632/
https://www.ncbi.nlm.nih.gov/pubmed/36389758
http://dx.doi.org/10.3389/fimmu.2022.1010270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647632/
https://www.ncbi.nlm.nih.gov/pubmed/36389758
http://dx.doi.org/10.3389/fimmu.2022.1010270

Ejemplares similares